$ARTV insider trading
Over the last 12 months, Artiva Biotherapeutics insiders reported 10 buys totaling $34.1M and 10 sales totaling $1.5M across SEC Form 4 filings. 30% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- $34.1M 10 events
- Sold · 12m
- $1.5M 10 events
- Events · 12m
- 20 Form 4 filings, grouped
- Insiders · 12m
- 6 distinct reporters
- 10b5-1 share
- 30% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Aslan FredChief Executive Officer · O·D | ▼ Sale | 23,429 | $10.92 | $256K | -1.6% | plan |
| Sep 3, 2026 | Horan ChristopherChief Tech Operations Officer · O | ▼ Sale | 10,366 | $11.16 | $116K | -3.5% | — |
| Sep 3, 2026 | Bush JenniferCOO, CLO, Compliance Officer · O | ▼ Sale | 8,391 | $11.16 | $94K | -2.5% | — |
| Sep 3, 2026 | Banerjee SubhashisChief Medical Officer · O | ▼ Sale | 1,100 | $11.16 | $12K | -0.8% | — |
| Sep 3, 2026 | Aslan FredChief Executive Officer · O·D | ▼ Sale | 61,888 | $11.16 | $690K | -4% | — |
| Aug 27, 2026 | Banerjee SubhashisChief Medical Officer · O | ▼ Sale | 8,222 | $12.01 | $99K | -5.5% | plan |
| Aug 18, 2026 | Banerjee SubhashisChief Medical Officer · O | ▼ Sale | 429 | $12 | $5K | -0.3% | plan |
| Jul 31, 2026 | RA CAPITAL MANAGEMENT, L.P.D·10% | ▲ Buy | 45,768 | $9.96 | $456K | +0.3% | 2 tranches · indirect |
| Jul 24, 2026 | RA CAPITAL MANAGEMENT, L.P.D·10% | ▲ Buy | 41,319 | $9.99 | $413K | +0.2% | indirect |
| Jul 23, 2026 | RA CAPITAL MANAGEMENT, L.P.D·10% | ▲ Buy | 264,586 | $9.76 | $2.6M | +1.6% | 3 tranches · indirect |
| Jul 17, 2026 | RA CAPITAL MANAGEMENT, L.P.D·10% | ▲ Buy | 160,354 | $8.93 | $1.4M | +1% | 2 tranches · indirect |
| Jul 13, 2026 | RA CAPITAL MANAGEMENT, L.P.D·10% | ▲ Buy | 21,654 | $8.96 | $194K | +0.1% | 2 tranches · indirect |
| Jun 26, 2026 | RA CAPITAL MANAGEMENT, L.P.D·10% | ▲ Buy | 32,876 | $8.89 | $292K | +0.2% | 2 tranches · indirect |
| Jun 16, 2026 | RA CAPITAL MANAGEMENT, L.P.D·10% | ▲ Buy | 531,326 | $8.66 | $4.6M | +3.3% | 3 tranches · indirect |
| Jun 11, 2026 | RA CAPITAL MANAGEMENT, L.P.D·10% | ▲ Buy | 1,027,722 | $7.44 | $7.7M | +6.8% | 3 tranches · indirect |
| May 11, 2026 | GC Corp.10% | ▲ Buy | 347,222 | $11.52 | $4.0M | +27.5% | late · indirect |
| May 11, 2026 | GC Corp.10% | ▲ Buy | 1,085,069 | $11.52 | $12.5M | +32.8% | late |
| Dec 15, 2025 | Aslan FredPresident and CEO · O·D | ▼ Sale | 3,187 | $6 | $19K | -0.3% | plan |
| Nov 17, 2025 | Aslan FredPresident and CEO · O·D | ▼ Sale | 6,375 | $3.38 | $22K | -1.8% | plan |
| Oct 17, 2025 | Aslan FredPresident and CEO · O·D | ▼ Sale | 25,500 | $6 | $153K | -6.7% | plan |
| Aug 15, 2025 | Aslan FredPresident and CEO · O·D | ▼ Sale | 25,500 | $2.73 | $70K | -6.2% | plan |
Every $ARTV filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Artiva Biotherapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $ARTV feed.